Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Regeneron Pharmaceuticals (REGN) stock in plain English

Free brief · no signupStart here
REGNPublished Nov 12, 2026
Regeneron Pharmaceuticals Inc
Healthcare · Biotechnology
Discovers, manufactures, and sells antibody medications treating eye diseases, inflammatory conditions, and cancer.
Assets:
VelocImmune PlatformProprietary mouse technology for discovering fully human monoclonal antibodies
Tarrytown and RensselaerPrimary research campus and large-scale biologic manufacturing plants in New York
Dupixent and EyleaFlagship biologic therapies generating the primary share of corporate revenue
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

91
OPS ScoreOperating finances
Latest quote
-2.35%$923.34
$95.50B
20.4×
$16.90B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 12, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was REGN. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Regeneron Pharmaceuticals (REGN) do?

Regeneron Pharmaceuticals Inc (REGN) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Discovers, manufactures, and sells antibody medications treating eye diseases, inflammatory conditions, and cancer. Develops medicines internally using its proprietary genetically engineered mouse platform to produce human antibodies. It is worth $95.50B on the market and sold $16.90B over the last year.

Market cap
$95.50B
P/E ratio
20.4×
Annual sales
$16.90B
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 12, 2026

Brands and businesses behind REGN

  • Dupixent: Treats eczema and asthma as a prescription biologic therapy co-developed with Sanofi for recurring royalty and profit splits.
  • Eylea: Treats wet macular degeneration and retinal diseases through injected medication sold directly to eye care specialists.
  • Libtayo: Treats advanced skin and lung cancers by selling an intravenous monoclonal antibody therapy to oncology clinics.
  • Kevzara: Treats rheumatoid arthritis through prescription self-injectable doses commercialized in partnership with Sanofi.
  • Inmazeb: Treats Ebola infection through an antibody mixture supplied directly to government stockpiles and relief agencies.

REGN’s flags, in plain English

Each flag is a number from Regeneron Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 12, 2026.

Low debt

Low debt, only 8% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 82.7% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Stupid Cash

Can pay this year's bills 3.4 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

One Big Customer

A large share of total revenue depends on collaboration profits from Dupixent and direct sales of Eylea. A large share of sales comes from a single customer. If that customer leaves or buys less, sales drop with it.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about REGN

How big is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals’ market cap is $95.50B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $16.90B: what customers paid the company over the last year, before any costs.

What is REGN’s P/E ratio?

REGN’s P/E ratio is 20.4×. Investors pay about 20.4 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with REGN?

The first risk note on the card is One Big Customer, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Regeneron Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. REGN’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card